Why the study?
To define the prevalence and clinical characteristics of pediatric thrombosis in subjects with inherited antithrombin deficiency.
What is the prevalence and clinical characteristics of pediatric thrombosis in subjects with inherited antithrombin deficiency?
What is the prevalence and clinical characteristics of pediatric thrombosis in subjects with inherited antithrombin deficiency?
In patients with inherited antithrombin deficiency, 7.5% develop thrombosis before 19 years of age, with adolescence and the neonatal period being high-risk periods.
May inform pediatric thrombosis risk in antithrombin deficiency; leaves open prospective validation before guiding screening.
Pediatric thromboembolism (≤18 years) is very rare (0.07-0.14/10,000/year) but may be more prevalent in children with severe thrombophilia (protein C, protein S or antithrombin deficiency). The aim of this study was to define the prevalence and clinical characteristics of pediatric thrombosis in subjects with inherited antithrombin deficiency. Our observational retrospective multicentric study from two countries recruited 968 patients of any age from 441 unrelated families with genetically, biochemically and functionally characterized antithrombin deficiency. Seventy-three subjects (7.5%) developed thrombosis before 19 years of age. Two high-risk periods for thrombosis were identified: adolescence (12-18 years, n=49) with thrombus localization (lower limb deep venous thrombosis or pulmonary embolism) and triggering factors common to adults (oral contraceptives, surgery or pregnancy); and the neonatal period (
No takes yet. Share an insight, caveat, or question.
Morena‐Barrio et al. (2019) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: